Effects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in Aβ+ and Aβ- dementia with Lewy bodies patients
Marlies Oosthoek·Charlotte E. Teunissen·Lisa Vermunt·Yuanqing Ye·Manon van Ingen·Marleen Koel-Simmelink·Everard G.B. Vijverberg·Satya Saxena·Steven Hersch·Michael Irizarry·Pallavi Sachdev·Sjors G. J. G. In ‘t Veld
Irsenontrine (E2027) is a potent and selective PDE9 inhibitor that increases cellular cGMP, essential for glutamatergic synaptic function, and was investigated as symptomatic treatment for dementia with Lewy bodies (DLB). A recent Phase 2 study suggested differences in clinical responses in irsenontrine-treated DLB patients depending on amyloid (Aβ) co-pathology. In this post-hoc CSF proteomic sub-study, we evaluated how protein levels and biological pathways changed from baseline in DLB partici